Sweden
# |
Name |
Price to Sales Ratio (P/S) |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
17,623.20 |
Jan. 14, 2025 | USD 0.45 | 23.08% |
|
Sweden |
|
2 |
13,325.69 |
Jan. 14, 2025 | USD 1.61 | 0.34% |
|
Sweden |
|
3 |
7,217.70 |
Jan. 14, 2025 | USD 4.07 | -5.72% |
|
Sweden |
|
4 |
4,733.10 |
Jan. 14, 2025 | USD 1.17 | -3.73% |
|
Sweden |
|
5 |
983.80 |
Jan. 14, 2025 | USD 0.29 | 0.68% |
|
Sweden |
|
6 |
827.21 |
Jan. 14, 2025 | USD 0.27 | -5.32% |
|
Sweden |
|
7 |
457.03 |
Jan. 14, 2025 | USD 0.20 | 1.12% |
|
Sweden |
|
8 |
132.66 |
Jan. 14, 2025 | USD 0.29 | 3.82% |
|
Sweden |
|
9 |
118.38 |
Jan. 14, 2025 | USD 0.10 | 0.68% |
|
Sweden |
|
10 |
93.02 |
Jan. 14, 2025 | USD 0.16 | -1.51% |
|
Sweden |
|
11 |
83.70 |
Jan. 14, 2025 | USD 0.90 | 9.88% |
|
Sweden |
|
12 |
74.15 |
Jan. 14, 2025 | USD 0.39 | 2.53% |
|
Sweden |
|
13 |
55.38 |
Jan. 14, 2025 | USD 0.19 | 33.40% |
|
Sweden |
|
14 |
54.13 |
Jan. 14, 2025 | USD 0.27 | 3.36% |
|
Sweden |
|
15 |
40.95 |
Jan. 14, 2025 | USD 0.80 | 0.68% |
|
Sweden |
|
16 |
37.22 |
Jan. 14, 2025 | USD 32.97 | -0.61% |
|
Sweden |
|
17 |
37.17 |
Jan. 14, 2025 | USD 0.11 | 1.48% |
|
Sweden |
|
18 |
33.16 |
Jan. 14, 2025 | USD 0.52 | 0.51% |
|
Sweden |
|
19 |
27.36 |
Jan. 14, 2025 | USD 0.39 | -0.45% |
|
Sweden |
|
20 |
26.17 |
Jan. 14, 2025 | USD 1.01 | -1.50% |
|
Sweden |
|
21 |
25.98 |
Jan. 14, 2025 | USD 17.87 | 3.09% |
|
Sweden |
|
22 |
25.60 |
Jan. 14, 2025 | USD 2.74 | 1.67% |
|
Sweden |
|
23 |
23.67 |
Jan. 14, 2025 | USD 0.16 | -0.98% |
|
Sweden |
|
24 |
22.63 |
Jan. 14, 2025 | USD 42.37 | 0.78% |
|
Sweden |
|
25 |
21.02 |
Jan. 14, 2025 | USD 0.56 | 4.18% |
|
Sweden |
|
26 |
17.97 |
Jan. 14, 2025 | USD 51.72 | -0.10% |
|
Sweden |
|
27 |
16.25 |
Jan. 14, 2025 | USD 1.41 | -1.50% |
|
Sweden |
|
28 |
15.87 |
Jan. 14, 2025 | USD 22.17 | -0.20% |
|
Sweden |
|
29 |
15.25 |
Jan. 14, 2025 | USD 0.22 | -6.29% |
|
Sweden |
|
30 |
14.41 |
Jan. 14, 2025 | USD 2.91 | -2.20% |
|
Sweden |
|
31 |
13.54 |
Jan. 14, 2025 | USD 0.94 | 2.12% |
|
Sweden |
|
32 |
12.77 |
Jan. 14, 2025 | USD 0.71 | -2.02% |
|
Sweden |
|
33 |
12.70 |
Jan. 14, 2025 | USD 0.11 | -0.86% |
|
Sweden |
|
34 |
12.48 |
Jan. 14, 2025 | USD 0.41 | 1.78% |
|
Sweden |
|
35 |
10.53 |
Jan. 14, 2025 | USD 0.13 | -10.15% |
|
Sweden |
|
36 |
10.04 |
Jan. 14, 2025 | USD 10.16 | -0.20% |
|
Sweden |
|
37 |
9.59 |
Jan. 14, 2025 | USD 1.88 | 0.68% |
|
Sweden |
|
38 |
9.31 |
Jan. 14, 2025 | USD 1.42 | 3.80% |
|
Sweden |
|
39 |
9.27 |
Jan. 14, 2025 | USD 0.20 | 2.06% |
|
Sweden |
|
40 |
8.87 |
Jan. 14, 2025 | USD 1.01 | 1.76% |
|
Sweden |
|
41 |
8.76 |
Jan. 14, 2025 | USD 2.09 | -2.04% |
|
Sweden |
|
42 |
8.30 |
Jan. 14, 2025 | USD 0.84 | -0.17% |
|
Sweden |
|
43 |
7.74 |
Jan. 14, 2025 | USD 0.21 | 0.68% |
|
Sweden |
|
44 |
7.71 |
Jan. 14, 2025 | USD 9.75 | -0.95% |
|
Sweden |
|
45 |
7.59 |
Jan. 14, 2025 | USD 0.08 | 2.99% |
|
Sweden |
|
46 |
7.25 |
Jan. 14, 2025 | USD 0.23 | 11.53% |
|
Sweden |
|
47 |
7.23 |
Jan. 14, 2025 | USD 0.12 | -10.06% |
|
Sweden |
|
48 |
7.13 |
Jan. 14, 2025 | USD 18.25 | 2.79% |
|
Sweden |
|
49 |
7.10 |
Jan. 14, 2025 | USD 0.15 | -2.28% |
|
Sweden |
|
50 |
6.99 |
Jan. 14, 2025 | USD 20.58 | 0.68% |
|
Sweden |
The Health Care company in Sweden with the highest Price to Sales Ratio (P/S) is OncoZenge AB (publ) (Stockholm Stock Exchange: ONCOZ.ST) at 17,623.20.
The Health Care company in Sweden with the lowest Price to Sales Ratio (P/S) is Actic Group AB (publ) (Stockholm Stock Exchange: ATIC.ST) at 0.18.
The top 10 Health Care companies in Sweden by Price to Sales Ratio (P/S) are OncoZenge AB (publ), Diamyd Medical AB (publ), Infant Bacterial Therapeutics AB (publ), Lipum AB (publ), Alzinova AB (publ), SpectraCure AB (publ), Isofol Medical AB (publ), Enorama Pharma AB (publ), Kancera AB (publ) and Nanologica AB (publ).
The bottom 10 Health Care companies in Sweden by Price to Sales Ratio (P/S) are Actic Group AB (publ), Dedicare AB (publ), Ellen AB (publ), Attendo AB (publ), ADDvise Group AB (publ), Ambea AB (publ), Boule Diagnostics AB (publ), Careium AB (Publ), Arcoma AB and Ortivus AB (publ).